Talawar Tx Inc.
Talawar Tx Inc., a Delaware biotech corporation, filed Amendment No. 2 to its S-4 registration statement for a proposed SPAC merger with JATT II Acquisition Corp. Under the Business Combination Agreement dated June 29, 2026, Talawar will become the public company via a reverse merger where JATT shareholders receive one Post-Closing Company share per JATT share. The deal values Talawar at $120 million in equity ($10.00/share), with a concurrent $225 million PIPE at the same $10.00 price for 22.5 million shares.
- Talawar Tx Inc. is merging with SPAC JATT II Acquisition Corp. via a Cayman Islands merger, with Talawar surviving as the public company.
- The Business Combination Agreement values Talawar at $120 million in equity, based on $10.00 per share.
- A concurrent PIPE financing will raise $225 million from institutional investors at $10.00 per share for 22.5 million shares.
- JATT's Chairman/CEO Dr. Someit Sidhu is also founder/CEO of Khanda Therapeutics, which licensed assets to Talawar, and is a significant Talawar stockholder.
- The Sponsor acquired 1.5 million Founder Shares for ~$0.014 per share and has agreed to surrender an additional 150,000 shares at Closing.
Price data unavailable.
The SPAC CEO's triple role — JATT Chairman/CEO, Talawar stockholder, and founder of the company that licensed Talawar's core assets — creates an unusually concentrated conflict of interest in a $120M biotech deal.
This is a biotech SPAC merger (SIC 2836) where the target's lead assets were licensed from an entity controlled by the SPAC's own CEO — an unusually intertwined structure even by SPAC market standards. The $225M PIPE alongside a $120M equity valuation suggests strong institutional demand despite the conflict.
Dr. Someit Sidhu serves as JATT Chairman/CEO, is a limited partner of the Sponsor, and is a significant Talawar stockholder whose company (Khanda Therapeutics) licensed assets to Talawar — creating multiple conflicts of interest in deal negotiations. The Sponsor's Founder Shares were acquired at ~$0.014 per share versus $10.00 for public investors, representing substantial built-in gain regardless of post-merger performance.